CD274 and neoplasm: Additionally, in an exploratory trial assessing the efficacy of ICIs in combination with CCRT for locally advanced cervical cancer, the addition of the anti-PD-1 agent toripalimab exhibited a favorable safety profile and achieved an ORR of 100%, with PD-L1 expression on tumor cells deemed non-essential for eligibility (22).